All In Biotech

Drug Trial Radar · NCT06661915

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
NIH
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs). ASTX727 is a combination of two drugs, cedazuridine and decitabine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with iadademstat may be more effective than ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative MPNs.

Conditions

  • Accelerated Phase Myeloproliferative Neoplasm
  • Blast Phase Myeloproliferative Neoplasm
  • Essential Thrombocythemia
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Myeloproliferative Neoplasm, Not Otherwise Specified
  • Polycythemia Vera
  • Primary Myelofibrosis
  • Secondary Myelofibrosis

Interventions

  • Biospecimen CollectionProcedure

    Undergo buccal swab and blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration and biopsy

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow aspiration and biopsy

  • Decitabine and CedazuridineDrug

    Given PO

  • IadademstatDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute leukemia response-complete (ALR-C) rateTime frame: Within 4 cycles (cycle length = 28 days)

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Coral Springs

    Coral Springs, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Doral

    Doral, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Hollywood

    Hollywood, Florida · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida · Recruiting

  • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia

    North Miami, Florida · Recruiting

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois · Recruiting

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois · Recruiting

  • UChicago Medicine Northwest Indiana

    Crown Point, Indiana · Recruiting

  • University of Kansas Clinical Research Center

    Fairway, Kansas · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas · Recruiting

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas · Recruiting

  • NYP/Weill Cornell Medical Center

    New York, New York · Recruiting

  • Carolinas Medical Center/Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Atrium Health Cabarrus/LCI-Concord

    Concord, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah · Recruiting

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.